Biojournals.com Latest TGN1412 Publications http://www.biojournals.com/TGN1412.html Latest publications on TGN1412 en-us biojournals@sci7.com hourly 1 2000-01-01T12:00+00:00 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=22222884 The Yin and Yang of Immunomodulatory Biologics: Assessing the Delicate Balance between Benefit and Risk. A number of therapeutic immunomodulatory biologics, including antibodies, ... http://dx.doi.org/10.1177/0192623311430237 Toxicol Pathol. 2012 Jan 5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=22136053 In vitro cytokine release assays: reducing the risk of adverse events in man. The induction of cytokine release is a common consequence of the ... http://dx.doi.org/10.4155/bio.11.272 Bioanalysis. 2011 Dec;3(23):2657-63. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=22074378 A predictive biomimetic model of cytokine release induced by TGN1412 and other therapeutic monoclonal antibodies. Human peripheral blood mononuclear cells (PBMC) are routinely used in ... http://dx.doi.org/10.3109/1547691X.2011.613419 J Immunotoxicol. 2012 Jan;9(1):34-42. Epub 2011 Nov 10. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=21931118 Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412. Human volunteers receiving TGN1412, a humanized CD28-specific monoclonal ... http://dx.doi.org/10.1182/blood-2010-12-319780 Blood. 2011 Dec 22;118(26):6772-82. Epub 2011 Sep 19. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=21821307 Ipilimumab (Yervoy) and the TGN1412 catastrophe. The development of the anti-CTLA-4 antibody (ipilimumab; marketed as ... http://dx.doi.org/10.1016/j.imbio.2011.07.005 Immunobiology. 2011 Jul 7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=21741383 Comparison of novel methods for predicting the risk of pro-inflammatory clinical infusion reactions during monoclonal antibody therapy. Two methods for predicting the risk of pro-inflammatory clinical infusion ... http://dx.doi.org/10.1016/j.jim.2011.06.022 J Immunol Methods. 2011 Aug 31;371(1-2):134-42. Epub 2011 Jun 30. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=21493088 Endothelial cells co-stimulate peripheral blood mononuclear cell responses to monoclonal antibody TGN1412 in culture. The failure of preclinical testing to predict the severity of the cytokine ... http://dx.doi.org/10.1016/j.cyto.2011.03.019 Cytokine. 2011 Jul;55(1):141-51. Epub 2011 Apr 13. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=21042496 TGN1412: From Discovery to Disaster. After a drug is confirmed as safe and efficacious in preclinical studies, ... http://dx.doi.org/10.4103/0975-1483.66810 J Young Pharm. 2010 Jul;2(3):332-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=20964641 Were monocytes responsible for initiating the cytokine storm in the TGN1412 clinical trial tragedy? The precise biological mechanisms that caused the TGN1412 clinical trial ... http://dx.doi.org/10.1111/j.1365-2249.2010.04264.x Clin Exp Immunol. 2010 Dec;162(3):516-27. doi: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=20880392 Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. BACKGROUND AND PURPOSE: In 2006, a life-threatening 'cytokine storm', not ... http://dx.doi.org/10.1111/j.1476-5381.2010.00922.x Br J Pharmacol. 2010 Oct;161(3):512-26. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=20880391 Primate testing of TGN1412: right target, wrong cell. The failure of toxicity studies in non-human primates to predict the ... http://dx.doi.org/10.1111/j.1476-5381.2010.00925.x Br J Pharmacol. 2010 Oct;161(3):509-11. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=20840438 Testing new drugs in naked apes and getting the dose right in their young. http://dx.doi.org/10.1111/j.1365-2125.2010.03782.x Br J Clin Pharmacol. 2010 Oct;70(4):467-70. doi: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=20558225 Practical approaches to dose selection for first-in-human clinical trials with novel biopharmaceuticals. Recent advances in our understanding of disease biology, biomarkers, new ... http://dx.doi.org/10.1016/j.yrtph.2010.06.007 Regul Toxicol Pharmacol. 2010 Nov;58(2):243-51. Epub 2010 Jun 15. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=20504348 Assessing agonistic potential of a candidate therapeutic anti-IL21R antibody. ABSTRACT: BACKGROUND: Selective neutralization of the IL21/IL21R signaling ... http://dx.doi.org/10.1186/1479-5876-8-50 J Transl Med. 2010 May 26;8:50. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=20477639 Monoclonal antibody-induced cytokine-release syndrome. Monoclonal antibodies (mAbs) are widely used in anti-inflammatory and ... http://dx.doi.org/10.1586/eci.09.31 Expert Rev Clin Immunol. 2009 Sep;5(5):499-521.